A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 1112 participants.
Also called NCT05056727
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,112 participants
- Sponsor
- Registry
-
NCT05056727 -
2021-001911-96
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Argentina, Brazil, Bulgaria, Canada, China, India, Italy, Japan, Malaysia, Mexico, Philippines, Poland, Puerto Rico, Russia, Spain, Taiwan, Thailand, Türkiye, Ukraine, Vietnam
- Registry status
- Terminated
Technical summary
Registry record NCT05056727. Randomized; quadruple masking; primary purpose treatment. Start 2021-09-30 (actual); primary completion 2024-02-07 (actual). Results posted on 2026-01-08.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Effect of Sodium Zirconium Cyclosilicate on Chronic Kidney Disease (CKD) Progression in Participants With CKD and Hyperkalaemia or at Risk of Hyperkalaemia
- Acronym
- STABILIZE-CKD
- Condition
- Renal Insufficiency, Chronic
- Condition
- Hyperkalemia
- Intervention (Drug)
- Sodium Zirconium Cyclosilicate (SZC)
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- Lisinopril
- Intervention (Drug)
- Valsartan
- Intervention (Drug)
- Irbesartan
- Lead sponsor
- AstraZeneca
Record details
- Record id
cardio:ct-nct05056727- Content hash
4c6e9d712ca33a54d29b6bc14baca93a2e8480b778027d3a21270dbd6f148eb1